Shield Therapeutics plc
Company Profile
Shield is a commercial stage specialty pharmaceutical company with a focus on addressing iron deficiency with its lead product Accrufer®/Feraccru® (ferric maltol). The Group has launched Accrufer® in the US and Feraccru® is commercialized in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive license agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of Accrufer® / Feraccru® in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. in the Republic of Korea, and with KYE Pharmaceuticals Inc. in Canada.
Accrufer®/Feraccru® has patent coverage until the mid-2030s
Accrufer®/Feraccru® are registered trademarks of the Shield Group
Investor Access
Management will hold a presentation for Investors through the digital platform, Investor Meet Company, on Wednesday 14 December 2022 at 4:30pm. Investors can sign up to Investor Meet Company for free, by clicking here:
| Event | Date |
| Year End | 31 December |
| Half Year End | 30 June |
| Preliminary Results* | May |
| Interim Results* | September |
| AGM* | June |
* Months based on previous announcements of this kind
